Hypermetabolism in ALS patients: an early and persistent phenomenon
- 848 Downloads
The malnutrition common among patients with ALS can be attributed in some cases to increased resting energy expenditure (REE). However, the origins and evolution of this hypermetabolism have yet to be fully elucidated. The aim of the present study was to monitor REE over time in patients with ALS and to identify factors that may explain any variation observed. ALS patients underwent nutritional, neurological and respiratory assessment every 6 months for 2 years (or until they died or became physically incapable of being examined). Sixty-one patients were studied. At inclusion, 47.5% exhibited hypermetabolism, with a mean measured REE (mREE) 19.7 ± 6.4% higher than the mean calculated REE (cREE) (P < 0.0001). The hypermetabolism persisted when mREE was normalized for fat free mass (FFM): 35.1 ± 4.2 versus 32.3 ± 4.7 kcal/kg day−1 (P = 0.02) in hypermetabolic and normometabolic patients, respectively. In univariate analysis, mREE was negatively correlated with age and positively correlated with BMI, FFM, energy and protein intakes, and albumin level. No correlation was found with neurological scores, disease characteristics, respiratory function and survival. Multivariate analysis revealed no significant factors. Only 10 of 45 patients in whom REE was measured at least twice changed their metabolic status. Neither mREE nor mREE/cREE varied significantly over time, despite deteriorating neurological, nutritional and respiratory parameters (P < 0.0001), and an increase in mREE/FFM (P = 0.01). This study confirms that about 50% of ALS patients are hypermetabolic, and 80% show no change in metabolic status over time. Thus, metabolic status (a clinically useful indicator of the need for nutritional support) can be determined early in the evolution of the disease. The origin of hypermetabolism in this context remains unknown, but growing evidence points to mitochondria as having an important role.
KeywordsAmyotrophic lateral sclerosis Motor neuron disease
The authors thank Marion Brandolini, dietician, Laboratory of Human Nutrition, for analysing food intake records and Mr. William Francis for reviewing the paper.
Conflicts of interest statement
The authors report no conflicts of interest.
- 5.Dupuis L, Oudart H, René F, Gonzalez de Aguila JL, Loeffler JP (2004) Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci USA 101:11159–11164. doi: 10.1073/pnas.0402026101 PubMedCrossRefGoogle Scholar
- 8.Harris JA, Benedict FG (1919) A biometric study of basal metabolism in man. Carnegie institute of Washington, Washington DC, publication number 279Google Scholar
- 10.Medical Research Council Aid to the investigation of peripheral nerve injuries (1943) In: Medical research Council. War memorandum, 2nd edn. His Majesty’s Stationery Office, London, pp 11–46Google Scholar
- 17.Shimizu T, Hayashi H, Tanabe H (1991) Energy metabolism of ALS patients under mechanical ventilation and tube feeding. Clin Neurol 31:255–259Google Scholar
- 20.Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases (1994) El Escorial “clinical limits of amyotrophic lateral sclerosis” workshop contributors. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 124(suppl):96–107. doi: 10.1016/0022-510X(94)90191-0 Google Scholar
- 21.The ALS (1996) CNTF treatment study (ACTS) phase I–II study group. The amyotrophic lateral sclerosis functional rating scale: assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 53:141–147Google Scholar
- 22.Vielhaber S, Kunz D, Winkler K, Wiedemann FR, Kirches E, Feistner H, Heinze HJ, Elger CE, Schubert W, Kunz WS (2000) Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain 123:1339–1348. doi: 10.1093/brain/123.7.1339 PubMedCrossRefGoogle Scholar